{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:44:44Z","timestamp":1785422684384,"version":"3.56.0"},"reference-count":52,"publisher":"American Association for Cancer Research (AACR)","issue":"3","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014569","name":"St. Vincent\u2019s Prostate Cancer Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Biochemical recurrence (BCR) of prostate cancer presents a clinical challenge with limited systemic treatment options beyond androgen deprivation therapy (ADT), which carries significant morbidity. Preclinical data suggest that lysosomal homeostasis, including cholesterol trafficking and pH regulation, is a therapeutic vulnerability in hormone-dependent cancers. We therefore conducted HITMAN-PC, a phase I trial evaluating suba-itraconazole (SI) and hydroxychloroquine (HCQ) in men with BCR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>The synergy of SI and HCQ was validated in hormone-sensitive and castration-resistant prostate cancer cell lines. The HITMAN-PC trial (NCT03513211) then used a rolling-six design to establish the maximum tolerated dose (MTD) and recommended phase II dose of HCQ with a fixed SI dosage (150 mg twice daily). Secondary endpoints included safety, PSA kinetics [PSA progression-free survival (PFS) and time to ADT], and exploratory pharmacokinetic and lipidomic profiling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Itraconazole showed dose-dependent cytotoxicity, with synergy in LNCaP-derived hormone-sensitive and -resistant lines. Eleven patients were enrolled. Two dose-limiting toxicities at HCQ 600 mg twice daily (grade 3 diarrhea and alanine aminotransferase elevation) defined this level as the MTD with SI 150 mg twice daily. Common adverse events were hypertension, QTc prolongation, diarrhea, and nausea; no grade 4 events occurred. No PSA declines \u226550% were observed although most patients achieved PSA stabilization. The median PSA-PFS, time to ADT, and metastasis-free survival were 5.5, 14.3, and 15.9 months, respectively. Lipidomic profiling revealed 240 treatment-associated lipid changes, with sphingomyelin and triacylglycerol species correlating with PSA-PFS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Despite limited clinical activity overall, the identified lipidomic signatures provide proof of concept for using plasma lipidomics to monitor pharmacodynamic activity in future metabolism-targeted trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>This study established a safe dose for HCQ and SI but found limited clinical efficacy in prostate cancer. Its significance lies in providing proof of biology that this combination alters systemic lipid metabolism. We identified specific plasma lipid species that correlate with clinical outcomes, highlighting the power of embedded biomarker analysis to generate valuable mechanistic insights and candidate biomarkers, even in the absence of a strong clinical response.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-26-0010","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T08:56:05Z","timestamp":1772787365000},"page":"687-697","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4290-717X","authenticated-orcid":false,"given":"Barak","family":"Talmor","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04fw0fr46","id-type":"ROR","asserted-by":"publisher"}],"name":"Kinghorn Cancer Centre 1 , St Vincents Hospital, Sydney, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1423-613X","authenticated-orcid":false,"given":"Stefano","family":"Marastoni","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre 2 , Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0172-8688","authenticated-orcid":false,"given":"Brandon","family":"Lau","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04fw0fr46","id-type":"ROR","asserted-by":"publisher"}],"name":"Kinghorn Cancer Centre 1 , St Vincents Hospital, Sydney, Australia."},{"name":"3Fiona Stanley Hospital, Perth, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8153-7544","authenticated-orcid":false,"given":"Andrew O.","family":"Yam","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04fw0fr46","id-type":"ROR","asserted-by":"publisher"}],"name":"Kinghorn Cancer Centre 1 , St Vincents Hospital, Sydney, Australia."},{"id":[{"id":"https:\/\/ror.org\/01b3dvp57","id-type":"ROR","asserted-by":"publisher"}],"name":"Garvan Institute of Medical Research 4 , Sydney, Australia."},{"name":"5School of Clinical Medicine, St Vincent\u2019s Healthcare Clinical Campus, Faculty of Medicine and Health, UNSW Sydney, Sydney, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9855-5789","authenticated-orcid":false,"given":"Nicole","family":"Yeung","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01b3dvp57","id-type":"ROR","asserted-by":"publisher"}],"name":"Garvan Institute of Medical Research 4 , Sydney, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4892-6008","authenticated-orcid":false,"given":"Hui-Ming","family":"Lin","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01b3dvp57","id-type":"ROR","asserted-by":"publisher"}],"name":"Garvan Institute of Medical Research 4 , Sydney, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7837-4382","authenticated-orcid":false,"given":"Zhu Juan","family":"Li","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre 2 , Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4099-0339","authenticated-orcid":false,"given":"Henry","family":"Woo","sequence":"additional","affiliation":[{"name":"6Chris O\u2019Brien Lifehouse, Camperdown, Australia."},{"id":[{"id":"https:\/\/ror.org\/017bddy38","id-type":"ROR","asserted-by":"publisher"}],"name":"Blacktown Hospital 7 Department of Urology, , Blacktown, Australia."},{"name":"8Blacktown Mount Druitt Clinical School, Western Sydney University, Blacktown, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1001-5658","authenticated-orcid":false,"given":"Ganes","family":"Pranavan","sequence":"additional","affiliation":[{"name":"9Canberra Health Services, Canberra, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0934-0656","authenticated-orcid":false,"given":"Phillip D.","family":"Stricker","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01b3dvp57","id-type":"ROR","asserted-by":"publisher"}],"name":"Garvan Institute of Medical Research 4 , Sydney, Australia."},{"name":"10St. Vincent\u2019s Prostate Cancer Research Centre, Sydney, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6842-9223","authenticated-orcid":false,"given":"Lisa G.","family":"Horvath","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01b3dvp57","id-type":"ROR","asserted-by":"publisher"}],"name":"Garvan Institute of Medical Research 4 , Sydney, Australia."},{"name":"5School of Clinical Medicine, St Vincent\u2019s Healthcare Clinical Campus, Faculty of Medicine and Health, UNSW Sydney, Sydney, Australia."},{"name":"6Chris O\u2019Brien Lifehouse, Camperdown, Australia."},{"name":"10St. Vincent\u2019s Prostate Cancer Research Centre, Sydney, Australia."},{"name":"11University of Sydney, Sydney, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0547-2480","authenticated-orcid":false,"given":"Marianne","family":"Koritzinsky","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre 2 , Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8187-592X","authenticated-orcid":false,"given":"Bradly G.","family":"Wouters","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre 2 , Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7213-900X","authenticated-orcid":false,"given":"Megan","family":"Crumbaker","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04fw0fr46","id-type":"ROR","asserted-by":"publisher"}],"name":"Kinghorn Cancer Centre 1 , St Vincents Hospital, Sydney, Australia."},{"id":[{"id":"https:\/\/ror.org\/01b3dvp57","id-type":"ROR","asserted-by":"publisher"}],"name":"Garvan Institute of Medical Research 4 , Sydney, Australia."},{"name":"5School of Clinical Medicine, St Vincent\u2019s Healthcare Clinical Campus, Faculty of Medicine and Health, UNSW Sydney, Sydney, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5159-4580","authenticated-orcid":false,"given":"Anthony M.","family":"Joshua","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04fw0fr46","id-type":"ROR","asserted-by":"publisher"}],"name":"Kinghorn Cancer Centre 1 , St Vincents Hospital, Sydney, Australia."},{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre 2 , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/01b3dvp57","id-type":"ROR","asserted-by":"publisher"}],"name":"Garvan Institute of Medical Research 4 , Sydney, Australia."},{"name":"5School of Clinical Medicine, St Vincent\u2019s Healthcare Clinical Campus, Faculty of Medicine and Health, UNSW Sydney, Sydney, Australia."},{"name":"10St. Vincent\u2019s Prostate Cancer Research Centre, Sydney, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"2026032711514223900_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2026032711514223900_bib2","volume-title":"Cancer of the prostate - cancer stat facts","author":"Surveillance, Epidemiology, and End Results Program","year":".."},{"key":"2026032711514223900_bib3","doi-asserted-by":"crossref","first-page":"764","DOI":"10.3390\/cancers16040764","article-title":"How the management of biochemical recurrence in prostate cancer will be modified by the concept of anticipation and incrementation of therapy","volume":"16","author":"Sciarra","year":"2024","journal-title":"Cancers"},{"issue":"16_suppl","key":"2026032711514223900_bib4","doi-asserted-by":"crossref","first-page":"5090","DOI":"10.1200\/JCO.2022.40.16_suppl.5090","article-title":"Recurrence, metastasis, and survival after radical prostatectomy in the era of advanced treatments","volume":"40","author":"Stensland","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026032711514223900_bib5","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/JU.0000000000001797","article-title":"Timing of androgen deprivation treatment for men with biochemical recurrent prostate cancer in the context of novel therapies","volume":"206","author":"Marshall","year":"2021","journal-title":"J Urol"},{"key":"2026032711514223900_bib6","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3390\/cancers17020215","article-title":"Early versus delayed androgen deprivation therapy for biochemical recurrence after local curative treatment in non-metastatic hormone-sensitive prostate cancer: a systematic review of the literature","volume":"17","author":"Karim","year":"2025","journal-title":"Cancers (Basel)"},{"key":"2026032711514223900_bib7","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0090-4295(02)02397-X","article-title":"Side effects of androgen deprivation therapy: monitoring and minimizing toxicity","volume":"61","author":"Higano","year":"2003","journal-title":"Urology"},{"key":"2026032711514223900_bib8","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.1200\/JCO.2018.36.15_suppl.5018","article-title":"Timing of androgen deprivation therapy for prostate cancer patients after radiation: planned combined analysis of two randomized phase 3 trials","volume":"36","author":"Loblaw","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026032711514223900_bib9","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1200\/JCO.22.00644","article-title":"Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials","volume":"40","author":"Deek","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026032711514223900_bib10","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"2026032711514223900_bib11","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved outcomes with enzalutamide in biochemically recurrent prostate cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"N Engl J Med"},{"key":"2026032711514223900_bib12","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-024-01808-1","article-title":"Drug repurposing for cancer therapy","volume":"9","author":"Xia","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"2026032711514223900_bib13","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3332\/ecancer.2015.521","article-title":"Repurposing Drugs in Oncology (ReDO)\u2013itraconazole as an anti-cancer agent","volume":"9","author":"Pantziarka","year":"2015","journal-title":"Ecancermedicalscience"},{"key":"2026032711514223900_bib14","doi-asserted-by":"crossref","first-page":"113616","DOI":"10.1016\/j.biopha.2022.113616","article-title":"Repurposed itraconazole for use in the treatment of malignancies as a promising therapeutic strategy","volume":"154","author":"Li","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"2026032711514223900_bib15","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.1128\/AAC.00973-15","article-title":"Population pharmacokinetic modeling of itraconazole and hydroxyitraconazole for oral SUBA-itraconazole and sporanox capsule formulations in healthy subjects in fed and fasted states","volume":"59","author":"Abuhelwa","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2026032711514223900_bib16","doi-asserted-by":"crossref","first-page":"e0013421","DOI":"10.1128\/AAC.00134-21","article-title":"Bioavailability of single-dose SUBA-itraconazole compared to conventional itraconazole under fasted and fed conditions","volume":"65","author":"Rauseo","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2026032711514223900_bib17","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.1016\/j.clgc.2018.09.013","article-title":"Itraconazole as a noncastrating treatment for biochemically recurrent prostate cancer: a phase 2 study","volume":"17","author":"Lee","year":"2019","journal-title":"Clin Genitourinary Cancer"},{"key":"2026032711514223900_bib18","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1634\/theoncologist.2012-314","article-title":"Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer","volume":"18","author":"Antonarakis","year":"2013","journal-title":"Oncologist"},{"key":"2026032711514223900_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/onc.2015.99","article-title":"Emerging strategies to effectively target autophagy in cancer","volume":"35","author":"Rebecca","year":"2016","journal-title":"Oncogene"},{"key":"2026032711514223900_bib20","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1093\/jac\/dkv018","article-title":"Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases","volume":"70","author":"Al-Bari","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2026032711514223900_bib21","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.canlet.2019.11.014","article-title":"FOXM1 contributes to docetaxel resistance in castration-resistant prostate cancer by inducing AMPK\/mTOR-mediated autophagy","volume":"469","author":"Lin","year":"2020","journal-title":"Cancer Lett"},{"key":"2026032711514223900_bib22","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1002\/pros.22487","article-title":"Effect of dual inhibition of apoptosis and autophagy in prostate cancer","volume":"72","author":"Saleem","year":"2012","journal-title":"Prostate"},{"key":"2026032711514223900_bib23","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13046-022-02293-6","article-title":"Targeting autophagy in prostate cancer: preclinical and clinical evidence for therapeutic response","volume":"41","author":"Ashrafizadeh","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"2026032711514223900_bib24","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1158\/2767-9764.CRC-22-0037","article-title":"Repurposing itraconazole and hydroxychloroquine to target lysosomal homeostasis in epithelial ovarian cancer","volume":"2","author":"Marastoni","year":"2022","journal-title":"Cancer Res Commun"},{"key":"2026032711514223900_bib25","doi-asserted-by":"crossref","first-page":"738177","DOI":"10.3389\/fonc.2021.738177","article-title":"Aberrant cholesterol metabolism in ovarian cancer: identification of novel therapeutic targets","volume":"11","author":"He","year":"2021","journal-title":"Front Oncol"},{"key":"2026032711514223900_bib26","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.3390\/cancers13184696","article-title":"Prostate cancer\u2014focus on cholesterol","volume":"13","author":"\u0160kara","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026032711514223900_bib27","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0303-7207(02)00363-5","article-title":"Androgen biosynthesis from cholesterol to DHEA","volume":"198","author":"Miller","year":"2002","journal-title":"Mol Cell Endocrinol"},{"key":"2026032711514223900_bib28","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/s41416-021-01435-5","article-title":"Metabolic reprogramming in prostate cancer","volume":"125","author":"Ahmad","year":"2021","journal-title":"Br J Cancer"},{"key":"2026032711514223900_bib29","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.plipres.2013.08.005","article-title":"Lipogenesis and lipolysis: the pathways exploited by the cancer cells to acquire fatty acids","volume":"52","author":"Zaidi","year":"2013","journal-title":"Prog Lipid Res"},{"key":"2026032711514223900_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.prostaglandins.2012.03.003","article-title":"Lipids and prostate cancer","volume":"98","author":"Suburu","year":"2012","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"2026032711514223900_bib31","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.eururo.2007.04.039","article-title":"The influence of lipid metabolism on prostate cancer development and progression: is it time for a closer look?","volume":"52","author":"Clarke","year":"2007","journal-title":"Eur Urol"},{"key":"2026032711514223900_bib32","doi-asserted-by":"crossref","first-page":"9132","DOI":"10.3390\/ijms26189132","article-title":"Reprogrammed lipid metabolism-associated therapeutic vulnerabilities in prostate cancer","volume":"26","author":"Parupathi","year":"2025","journal-title":"Int J Mol Sci"},{"key":"2026032711514223900_bib33","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41467-019-13917-5","article-title":"Structural basis for itraconazole-mediated NPC1 inhibition","volume":"11","author":"Long","year":"2020","journal-title":"Nat Commun"},{"key":"2026032711514223900_bib34","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1073\/pnas.1619571114","article-title":"Triazoles inhibit cholesterol export from lysosomes by binding to NPC1","volume":"114","author":"Trinh","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026032711514223900_bib35","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1021\/acschembio.6b00849","article-title":"Simultaneous targeting of NPC1 and VDAC1 by itraconazole leads to synergistic inhibition of mTOR signaling and angiogenesis","volume":"12","author":"Head","year":"2017","journal-title":"ACS Chem Biol"},{"key":"2026032711514223900_bib36","doi-asserted-by":"crossref","first-page":"e185ms2947","DOI":"10.54905\/disssi\/v27i134\/e185ms2947","article-title":"The effects of terbinafine on the lipid profile in humans and rabbits","volume":"27","author":"Alsuwaidan","year":"2023","journal-title":"Med Sci"},{"key":"2026032711514223900_bib37","first-page":"1037","article-title":"The inhibitory effect of Itraconazole on atherosclerosis in hyperlipidemic rabbits","volume":"11","author":"Mohammad","year":"2014","journal-title":"Biosciences Biotechnol Res Asia"},{"key":"2026032711514223900_bib38","doi-asserted-by":"crossref","first-page":"902","DOI":"10.3899\/jrheum.131156","article-title":"Effect of hydroxychloroquine on the lipid profile of patients with Sj\u00f6gren syndrome","volume":"41","author":"Migkos","year":"2014","journal-title":"J Rheumatol"},{"key":"2026032711514223900_bib39","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/1756-185X.13159","article-title":"Favorable effects of hydroxychloroquine on serum low density lipid in patients with systemic lupus erythematosus: a systematic review and meta-analysis","volume":"21","author":"Babary","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"2026032711514223900_bib40","doi-asserted-by":"crossref","first-page":"e0152861","DOI":"10.1371\/journal.pone.0152861","article-title":"Combined AKT and MEK pathway blockade in pre-clinical models of enzalutamide-resistant prostate cancer","volume":"11","author":"Toren","year":"2016","journal-title":"PLoS One"},{"key":"2026032711514223900_bib41","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","article-title":"SynergyFinder plus: toward better interpretation and annotation of drug combination screening datasets","volume":"20","author":"Zheng","year":"2022","journal-title":"Genomics Proteomics Bioinformatics"},{"key":"2026032711514223900_bib42","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.clgc.2013.11.015","article-title":"High-dose itraconazole as a noncastrating therapy for a patient with biochemically recurrent prostate cancer","volume":"12","author":"Suzman","year":"2014","journal-title":"Clin Genitourin Cancer"},{"key":"2026032711514223900_bib43","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2165\/00003495-199651040-00006","article-title":"Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections","volume":"51","author":"Haria","year":"1996","journal-title":"Drugs"},{"key":"2026032711514223900_bib44","first-page":"145","article-title":"Insights from pharmacokinetic and pharmacodynamic studies of hydroxychloroquine","volume":"44","author":"Tett","year":"1993","journal-title":"Agents Actions Suppl"},{"key":"2026032711514223900_bib45","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/art.39402","article-title":"Association of polymorphisms of cytochrome P450 2D6 with blood hydroxychloroquine levels in patients with systemic lupus erythematosus","volume":"68","author":"Lee","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2026032711514223900_bib46","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.chembiol.2018.10.008","article-title":"High-throughput plasma lipidomics: detailed mapping of the associations with cardiometabolic risk factors","volume":"26","author":"Huynh","year":"2019","journal-title":"Cell Chem Biol"},{"key":"2026032711514223900_bib47","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/ijc.30903","article-title":"A distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancer","volume":"141","author":"Lin","year":"2017","journal-title":"Int J Cancer"},{"key":"2026032711514223900_bib48","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"2026032711514223900_bib49","volume-title":"LiverTox: clinical and research information on drug-induced liver injury","author":"Itraconazole","year":"2012"},{"key":"2026032711514223900_bib50","first-page":"e8415","article-title":"Serious adverse events associated with hydroxychloroquine amidst COVID-19 pandemic: case series and literature review","volume":"12","author":"Abdelmaseih","year":"2020","journal-title":"Cureus"},{"key":"2026032711514223900_bib51","first-page":"17","article-title":"Mineralocorticoid hypertension and hypokalaemia induced by posaconazole","volume":"2018","author":"Boughton","year":"2018","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"2026032711514223900_bib52","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.ctrv.2013.03.003","article-title":"Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone","volume":"39","author":"Pia","year":"2013","journal-title":"Cancer Treat Rev"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-26-0010\/3745996\/crc-26-0010.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/3\/687\/3755220\/crc-26-0010.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/3\/687\/3755220\/crc-26-0010.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T15:51:53Z","timestamp":1774626713000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/3\/687\/776538\/A-Phase-I-Study-of-Hydroxychloroquine-and-Suba"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-26-0010","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.31872533","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31872521","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31872512","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31872500","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31872503","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31872527","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31872524","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31872536","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31872515","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31872518","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31872506","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31872509","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31872530","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31872497","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8387594","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,1]]}}}